Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1055 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
BRIEF COMMUNICATION
Year : 2016  |  Volume : 20  |  Issue : 1  |  Page : 137-141

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting


1 Excel Center (Initiative of Excelcare Hospitals), Guwahati, Assam, India
2 BRIDE (Bharti Hospital and Research Center), Karnal, Haryana, India

Correspondence Address:
Manash P Baruah
Excel Centre (An Initiative of Excelcare Hospitals), Barthakur Mill Road, Ulubari, Guwahati - 781 007, Assam
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.172265

Rights and Permissions

Objective: This study is aimed to evaluate the characteristics, treatment, and outcomes of patients treated with canagliflozin in the real-world setting within the first 4 months of the product's availability in India. Patients and Methods: It is a retrospective study with data collected from Indian clinical database. Patients aged 18 and above who were prescribed canagliflozin were included in this study. All the patients were on other antihyperglycemic agents (AHAs) before the initiation of canagliflozin. Results: Overall, nine patients were included in the study, and data for these patients with mean duration of follow-up of 16 weeks was analyzed. Mean age was 47.9 years and mean duration of type 2 diabetes was 6.7 years. Among patients with available laboratory data at baseline and follow-up, mean glycosylated hemoglobin A1c (HbA1c) decreased from 9.0% at baseline to 6.8% at follow-up (P < 0.005); mean weight reduced from 69.9 kg at baseline to 67.9 kg at follow-up. When compared to baseline, the usage and or dose of other AHAs were reduced during follow-up. Conclusion: Canagliflozin after it became available in India, improved all glycemic parameters and also reduced the weight of the type two diabetic patients who were poorly controlled by multiple AHAs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed873    
    Printed8    
    Emailed0    
    PDF Downloaded297    
    Comments [Add]    
    Cited by others 2    

Recommend this journal